Sigilon Uncovers Possible Reason Behind Hemophilia A Trial Hold

Shares of Sigilon Therapeutics are down this morning after the company announced it may have discovered the reason why its experimental cell therapy treatment for severe hemophilia A was placed on clinical hold earlier this year by the U.S. Food and Drug Administration (FDA).